Project Grant R44AI181290
Award Date
6/20/24
Completion Date
5/31/25
Dollars Obligated
$270K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Oncosting, LLC (DJXQC89K4S79)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This $1,162,224 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to optimize and evaluate the efficacy of an oral Bacille Calmette-Guerin (BCG) vaccine regimen against tuberculosis (TB). The key objectives are to: 1) Optimize an oral BCG vaccination approach, 2) Compare the efficacy of oral BCG to standard intradermal and intravenous BCG vaccination in a non-human primate model...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to better understand the differences in protective efficacy between different Bacillus Calmette-Guérin (BCG) vaccine sub-strains used to prevent tuberculosis (TB). The $749,192 award, spanning from November 2024 to October 2029, will enable Texas A&M University System Health Science Center (TAMU HSC)...
This federal Project Grant award, totaling $859,597.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary objective is to develop a novel vaccine candidate that can elicit broadly neutralizing antibodies against the HIV-1 fusion peptide epitope. Key aspects of the project include: Laying the groundwork for an innovative vaccine approach using an AB toxin B subunit, such as...
This $817,405 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new 3-4 drug regimens for the treatment of drug-sensitive and drug-resistant tuberculosis (TB). The primary goals are to (1) manufacture and characterize dry powder formulations of the spectinamide compound LEE-1810 for inhalation delivery, (2) determine the optimal dose and dosing frequency of the BPAS...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
This federal Project Grant award of $787,171, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of new antituberculosis (TB) compounds based on 1,2,4-triazole and pyrrolidine scaffolds. The primary awardee, Washington University in St. Louis, aims to demonstrate preclinical proof-of-concept for these compounds, optimize lead candidates for pharmacological properties, and...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $517,185 award, with a performance period from August 1, 2024 to June 30, 2026, will fund research to characterize the immune response to tuberculosis (TB) using integrated single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will generate multi-omic data, including...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $950,092 to Seattle Children's Research Institute to develop two innovative vaccine candidates against nontuberculous mycobacterial (NTM) lung infections. The key products and services to be delivered include: The development and evaluation of an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine,...
This $749,414 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary awardee, The Ohio State University, is conducting research to investigate the role of the macrophage efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and its impact on tuberculosis (TB) treatment duration. The research aims to: 1) define the role of MDR1 in M.TB survival in macrophages;...